Real world Indian experience of switchover to Bilastine in CSU patient refractory to other antihistamines

---

Original Article

Author Details : Bela Shah, DBN Murthy, Atul Kochhar, Dhiraj Dhoot*, Rashmi KM

Volume : 6, Issue : 4, Year : 2020

Article Page : 328-332

https://doi.org/10.18231/j.ijced.2020.066

Suggest article by email

Get Permission

---

Abstract

Background: Second generation anti histamines are first line therapy as recommended by many guidelines for Chronic spontaneous urticaria (CSU). Bilastine, non-sedative H1-antihistamine is recently approved in India for the management of CSU.
Materials and Methods: A real world retrospective study was conducted across India to assess the  response of CSU patients who were switched over to bilastine after non satisfactory response to other antihistamines at 140 dermatology clinics.
Results: A data of 518 patients’ were included in this analysis. Mean age of the patients was 35.3 12.3 years while mean disease duration was 7.089.3 months. Baseline mean UCT score of 8.6 3.02 was improved to 13.05 2.9 in 28 days (p<0> Conclusion: Authors concluded that in patients with inadequate response to commonly used antihistamines at licensed dose, switch over to bilastine resulted, not only in reliving the symptoms of CSU but also added to the Patients’ satisfaction with the drug.

Keywords: Bilastine, Urticaria antihistamines, Real world, Refractory.

How to cite : Shah B, Murthy D, Kochhar A, Dhoot D , Rashmi Km, Real world Indian experience of switchover to Bilastine in CSU patient refractory to other antihistamines. IP Indian J Clin Exp Dermatol 2020;6(4):328-332

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.